DFDA

SGLT2 Inhibitors (e.g., Dapagliflozin)

Treatment for Dilated Cardiomyopathy

Typical Dosage: Dapagliflozin 10mg daily

Effectiveness
92%
Safety Score
65%
Clinical Trials
25
Participants
25K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
Dapagliflozin 10mg daily
Time to Effect
1-4 weeks
Treatment Duration
lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
20(Treat 20 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$6,000
Monitoring:$700
Side Effect Mgmt:$150
Total Annual:$6,850
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$40,000/QALY
QALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$9,786
Cost per Remission
$137,000
Comparison vs Standard Medical Therapy
Cost Difference
+$6,000/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
SGLT2 Inhibitors (e.g., Dapagliflozin) Outcomes

for Dilated Cardiomyopathy

Efficacy Outcomes
Overall Effectiveness
+92%
Response Rate
+70%
Remission Rate
+5%
Common Side Effects
Genital mycotic infections
+8%
Urinary tract infections
+6%
Volume depletion/Hypotension
+3%

Sources:

nih.gov
nih.gov
oup.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov